

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant(s): Dunstan et al.

Serial No.: 09/389,782

Filed: September 3, 1999

For: OPG Fusion Protein Compositions and Methods

Docket No.: A-604



Group Art Unit No.: 1642

Examiner: Helms, L.

#12  
60  
71-01

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Robert B. Winter".

Robert B. Winter  
Attorney/Agent for Applicant(s)  
Registration No.: 34, 458  
Phone: (805) 447-2425  
Date: January 22, 2001

Please send all future correspondence to:

U.S. Patent Operations/RBW  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

January 22, 2001

Date

A handwritten signature in black ink, appearing to read "D. Della".  
Signature

Modified Form PTO-1449

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

A-604

Serial No.

09/389,782

Applicant

Dunstan et al.

Filing Date

September 3, 1999

Group

1642

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	4,710,473	12/1/87	Morris			
	A2	5,169,318	12/08/92	Levy			
	A3	5,447,851	09/05/95	Beutler et al			

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	B1	7-054977 ✓	7/21/95	Japan			X
	B2	7-207508 ✓	2/20/95	Japan			X
	B3	WO 95/11308 ✓	4/27/95	PCT			
	B4	WO 96/26217 ✓	8/29/96	PCT			X
	B5	WO 96/28546 ✓	9/19/96	PCT			
	B6	WO 98/12344 ✓	3/26/98	PCT			
	B7	WO 00/24416 ✓	5/04/00	PCT			X
	B8	WO 00/54651 ✓	9/21/00	PCT			

EXAMINER'S  
INITIALS

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Adams et al, Science, <u>252</u> , 1651-1656 (1991) ✓ 1656 ?
	C2	Banner et al, Cell, <u>73</u> , 431-445 (1993) ✓
	C3	Beutler and van Huffel, Science, <u>264</u> , 667-663 (1994) ✓
	C4	Beutler et al, Ann. Rev. Biochem., <u>57</u> , 505-518 (1988) ✓
	C5	Boyce et al, Endocrinology, <u>125</u> , 1142-1150 (1989) ✓
	C6	Brinster et al., Proc. Natl. Acad. Sci. USA, <u>82</u> , 4338 (1985) ✓
	C7	Capon et al, Nature, <u>337</u> , 525-531 (1989) ✓
	C8	Chen et al., Chemistry, <u>270</u> , 2874-2878 (1995) ✓

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

A-604

Serial No.

09/389,782

Applicant

Dunstan et al.

Filing Date

September 3, 1999

Group

1642

EXAMINER'S  
INITIALS

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C9	Chomczynski and Sacchi, Anal. Biochem., <u>162</u> , 156-159, (1987)	✓
C10	Chou and Fasman, Adv. Enz., <u>47</u> , 45-147 (1948)	✓
C11	DeClerck et. al, J. Biol. Chem., <u>266</u> , 3893 (1991)	✓
C12	Eisenberg et al, PNAS USA, <u>81</u> , 140-144 (1984)	✓
C13	Ellison et al, Nuc. Acids Res., <u>10</u> , 4071-4079 (1982)	✓
C14	Engelman et al, Ann. Rev. Biophys. Biophys. Chem., <u>15</u> , 321-353 (1986)	✓
C15	Fisher et al, Cell, <u>81</u> , 935-946 (1995)	✓
C16	Gennaro A.R., <u>Remington's Pharmaceutical Sciences</u> , 18th ed. Mack, Easton, PA (1980)	✓
C17	Goeddel et al, Cold Spring Harbor Symp. Quart. Biol., <u>51</u> , 597-609 (1986)	✓
C18	Goeddel, D.V., <u>Methods of Enzymology</u> , v. 185, ed. Academic Press (1990)	✓
C19	Gribskov et al, PNAS USA, <u>83</u> , 4355-4359 (1987)	✓
C20	Harlow and Lane, <u>Antibodies: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y. (1988)	✓
C21	Heldin, Cell, <u>80</u> , 213-223 (1995)	✓
C22	Kohno et al, PNAS USA, <u>87</u> , 8331-8335 (1990)	✓
C23	Kraulis, J. Appl. Cryst., <u>24</u> , 946-950, 1991)	✓
C24	Kwon et al, FASEB Journal, <u>12</u> , 845-854 (1998)	✓
C25	Kyte and Doolittle, J. Mol. Biol., <u>157</u> , 105-132 (1982)	✓

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

A-604

Serial No.

09/389,782

Applicant

Dunstan et al.

Filing Date

September 3, 1999

Group

1642

EXAMINER'S  
INITIALS

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C26	Lewis et al., PNAS USA, <u>88</u> , 2830-2834 (1991)	✓
	C27	Loetscher et al, Cancer Cells, <u>3(6)</u> , 221-226 (1991)	✓
	C28	Lüthy et al, Protein Science, <u>3</u> , 139-146 (1994)	✓
	C29	Maitland et al, Cell, <u>11</u> , 233-241 (1977)	✓
	C30	Matsudaira et al, J. Biol. Chem., <u>262</u> , 10-35 (1987)	✓
	C31	McDonald et al, Meth. Enzymol., <u>152</u> , 219 (1987)	✓
	C32	Nagata et al, Science, <u>267</u> , 1449-1456 (1995)	✓
	C33	Ogden et al, Meth. Enzymol., <u>152</u> , 61 (1987)	✓
	C34	Pearson et al, Meth. Enzymol., <u>183</u> , (1990)	✓
	C35	Simonet et al, J. Clin. Invest., <u>94</u> , 1310-1319 (1994)	✓
	C36	Simonet et al, <u>Cell</u> , 89, 309-319 (1997)	✓
	C37	Smith, et al, Cell, <u>76</u> , 953-962 (1994)	✓
	C38	Suda et al, Cell, <u>75</u> , 1169-1178 (1993)	✓
	C39	Tsuda et al, Biochem. & Biophys. Res.Comm., <u>234</u> , 137-142 (1997)	✓
	C40	Udagawa et al, PNAS USA, <u>87</u> , 7260-7264 (1990)	✓
	C41	Udagawa et al, Endocrinology, <u>125</u> , 1805-1813 (1989)	✓
	C42	Yan et al, J. Biol. Chem., <u>266</u> , 12099-12104 (1994)	✓

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449

Att'y. Docket No.

A-604

Serial No.

09/389,782

### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Dunstan et al.

Filing Date

September 3, 1999

Group	Mean	SD	95% CI
Control	1.0	0.0	1.0
Low	1.0	0.0	1.0
High	1.0	0.0	1.0

1642

EXAMINER'S  
INITIALS

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

[illegible]

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.